SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "LAR1:gu ;pers:(Blennow Kaj 1958)"

Sökning: LAR1:gu > Blennow Kaj 1958

  • Resultat 61-70 av 1860
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
61.
  • Andreasson, Ulf, 1968, et al. (författare)
  • A Practical Guide to Immunoassay Method Validation.
  • 2015
  • Ingår i: Frontiers in neurology. - : Frontiers Media SA. - 1664-2295. ; 6
  • Tidskriftsartikel (refereegranskat)abstract
    • Biochemical markers have a central position in the diagnosis and management of patients in clinical medicine, and also in clinical research and drug development, also for brain disorders, such as Alzheimer's disease. The enzyme-linked immunosorbent assay (ELISA) is frequently used for measurement of low-abundance biomarkers. However, the quality of ELISA methods varies, which may introduce both systematic and random errors. This urges the need for more rigorous control of assay performance, regardless of its use in a research setting, in clinical routine, or drug development. The aim of a method validation is to present objective evidence that a method fulfills the requirements for its intended use. Although much has been published on which parameters to investigate in a method validation, less is available on a detailed level on how to perform the corresponding experiments. To remedy this, standard operating procedures (SOPs) with step-by-step instructions for a number of different validation parameters is included in the present work together with a validation report template, which allow for a well-ordered presentation of the results. Even though the SOPs were developed with the intended use for immunochemical methods and to be used for multicenter evaluations, most of them are generic and can be used for other technologies as well.
  •  
62.
  • Andreasson, Ulf, 1968, et al. (författare)
  • Aspects of beta-amyloid as a biomarker for Alzheimer's disease
  • 2007
  • Ingår i: Biomarkers in Medicine. - : Future Medicine Ltd. - 1752-0363 .- 1752-0371. ; 1:1, s. 59-78
  • Forskningsöversikt (refereegranskat)abstract
    • Alzheimer’s disease is an age-related neurodegenerative disorder that results in progressive cognitive impairment and death. The accumulation of β-amyloid (Aβ) in specific brain regions is believed by many to represent the earliest event in the pathogenesis of the disease. Here, we review the key aspects of Aβ as a biomarker for Alzheimer’s disease, including the pathogenicity of Aβ, the possible biological functions of its precursor protein, the Aβ metabolism and homeostasis, the diagnostic performance of different Aβ assays in different settings and the potential usefulness of Aβ as a surrogate marker for treatment efficacy in clinical trials of novel Aβ-targeting drugs against Alzheimer’s disease.
  •  
63.
  • Andreasson, Ulf, 1968, et al. (författare)
  • Assessing the commutability of candidate reference materials for the harmonization of neurofilament light measurements in blood
  • 2023
  • Ingår i: Clinical Chemistry and Laboratory Medicine. - : Walter de Gruyter GmbH. - 1434-6621 .- 1437-4331. ; 61:7, s. 1245-1254
  • Tidskriftsartikel (refereegranskat)abstract
    • Objectives Neurofilament light chain (NfL) concentration in blood is a biomarker of neuro-axonal injury in the nervous system and there now exist several assays with high enough sensitivity to measure NfL in serum and plasma. There is a need for harmonization with the goal of creating a certified reference material (CRM) for NfL and an early step in such an effort is to determine the best matrix for the CRM. This is done in a commutability study and here the results of the first one for NfL in blood is presented.Methods Forty paired individual serum and plasma samples were analyzed for NfL on four different analytical platforms. Neat and differently spiked serum and plasma were evaluated for their suitability as a CRM using the difference in bias approach.Results The correlation between the different platforms with regards to measured NfL concentrations were very high (Spearman's rho >= 0.96). Samples spiked with cerebrospinal fluid (CSF) showed higher commutability compared to samples spiked with recombinant human NfL protein and serum seems to be a better choice than plasma as the matrix for a CRM.Conclusions The results from this first commutability study on NfL in serum/plasma showed that it is feasible to create a CRM for NfL in blood and that spiking should be done using CSF rather than with recombinant human NfL protein.
  •  
64.
  • Andreasson, Ulf, 1968, et al. (författare)
  • Commutability of the certified reference materials for the standardization of beta-amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and beta-amyloid 1-40 measurements
  • 2018
  • Ingår i: Clinical Chemistry and Laboratory Medicine. - : Walter de Gruyter GmbH. - 1434-6621 .- 1437-4331. ; 56:12, s. 2058-2066
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: The core Alzheimer's disease cerebrospinal fluid (CSF) biomarkers total tau (T-tau), phosphorylated tau (P-tau), beta-amyloid 1-42 (A beta 42) and beta-amyloid 1-40 (A beta 40) are increasing in importance and are now part of the research criteria for the diagnosis of the disease. The main aim of this study is to evaluate whether a set of certified reference materials (CRMs) are commutable for A beta 42 and to serve as a feasibility study for the other markers. This property is a prerequisite for the establishment of CRMs which will then be used by manufacturers to calibrate their assays against. Once the preanalytical factors have been standardized and proper selection criteria are available for subject cohorts this harmonization between methods will allow for universal cut-offs to be determined. Methods: Thirty-four individual CSF samples and three different CRMs where analyzed for T-tau, P-tau, A beta 42 and A beta 40, using up to seven different commercially available methods. For A beta 40 and A beta 42 a mass spectrometry-based procedure was also employed. Results: There were strong pairwise correlations between the different methods (Spearman's p>0.92) for all investigated analytes and the CRMs were not distinguishable from the individual samples. Conclusions: This study shows that the CRMs are commutable for the different assays for A beta 42. For the other analytes the results show that it would be feasible to also produce CRMs for these. However, additional studies are needed as the concentration interval for the CRMs were selected based on A beta 42 concentrations only and did in general not cover satisfactory large concentration intervals for the other analytes.
  •  
65.
  •  
66.
  • Andreasson, Ulf, 1968, et al. (författare)
  • Method and Clinical Validation of Biomarkers for Neurodegenerative Diseases
  • 2021
  • Ingår i: Cerebrospinal Fluid Biomarkers. Neuromethods, vol 168. Teunissen C.E., Zetterberg H. (eds). - New York, NY : Springer. - 0893-2336. - 9781071613184 ; , s. 163-173
  • Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
    • In the Merriam-Webster dictionary, one definition of the word valid is “well-grounded or justifiable: being at once relevant and meaningful.” Validation is then the process of determining the degree of validity. From this broad definition, it follows that validations can be made in many different fields with quite different implications. When talking about validation, it is therefore important to specify the subject under scrutiny and in this chapter the focus will be on validation of biomarkers. © 2021, Springer Science+Business Media, LLC, part of Springer Nature.
  •  
67.
  • Andreasson, Ulf, 1968, et al. (författare)
  • Multiplexing and multivariate analysis in neurodegeneration.
  • 2012
  • Ingår i: Methods (San Diego, Calif.). - : Elsevier BV. - 1095-9130 .- 1046-2023. ; 56:4, s. 464-70
  • Tidskriftsartikel (refereegranskat)abstract
    • Limited sample volume is often an obstacle in clinical research and one way to circumvent this is to use multiplex techniques where several different analytes are simultaneously measured. There is a multitude of different platforms that can be used for multiplexing and their uniqueness and similarities will be described. Multivariate analysis is a powerful tool for extracting information from multiplex data. An introduction to one such algorithm is presented followed by examples from the literature, in the field of neurodegeneration, where multiplex and multivariate methods have been used.
  •  
68.
  • Andreasson, Ulf, 1968, et al. (författare)
  • Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders.
  • 2016
  • Ingår i: Alzheimer's & dementia (Amsterdam, Netherlands). - : Wiley. - 2352-8729. ; 3, s. 98-102
  • Tidskriftsartikel (refereegranskat)abstract
    • Most research on fluid biomarkers for central nervous system (CNS) disorders has so far been performed using cerebrospinal fluid (CSF) as the biomarker source. CSF has the advantage of being closer to the brain than serum or plasma with a relative enrichment of CNS-specific proteins that are present at very low concentrations in the blood and thus difficult to reliably quantify using standard immunochemical technologies. Recent technical breakthroughs in the field of ultrasensitive assays have started to change this. Here, we review the most established ultrasensitive quantitative technologies that are currently available to general biomarker laboratories and discuss their use in research on biomarkers for CNS disorders.
  •  
69.
  • Andreou, D., et al. (författare)
  • Lower plasma total tau in adolescent psychosis: Involvement of the orbitofrontal cortex
  • 2021
  • Ingår i: Journal of Psychiatric Research. - : Elsevier BV. - 0022-3956 .- 1879-1379. ; 144, s. 255-261
  • Tidskriftsartikel (refereegranskat)abstract
    • Schizophrenia is thought to be a neurodevelopmental disorder with neuronal migration, differentiation and maturation disturbances. Tau is a microtubule-associated protein with a crucial role in these processes. Lower circulating tau levels have been reported in adults with schizophrenia, but this association has not been investigated in adolescent psychosis. We aimed to test the hypotheses that a) adolescents with early-onset psychosis (EOP; age of onset <18 years) display lower plasma tau concentrations compared to healthy controls, and b) among patients with psychosis, tau levels are linked to structural brain measures associated with the microtubule-associated tau (MAPT) gene and psychosis. We included 37 adolescent patients with EOP (mean age 16.4 years) and 59 adolescent healthy controls (mean age 16.2 years). We investigated putative patient-control differences in plasma total tau concentrations measured by a Single molecule array (Simoa) immunoassay. We explored the correlations between tau and selected structural brain measures based on T1-weighted MRI scans processed in FreeSurfer v6.0. We found significantly lower plasma tau concentrations in patients compared to healthy controls (p = 0.017, partial eta-squared = 0.061). Tau was not associated with antipsychotic use or the antipsychotic dosage. Among patients but not healthy controls, tau levels were positively correlated with the cortical orbitofrontal surface area (p = 0.013, R-squared = 0.24). The results are suggestive of a tau-related neurodevelopmental disturbance in adolescent psychosis.
  •  
70.
  • Antonell, Anna, et al. (författare)
  • Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias.
  • 2020
  • Ingår i: Alzheimer's & dementia : the journal of the Alzheimer's Association. - : Wiley. - 1552-5279. ; 16:2, s. 262-272
  • Tidskriftsartikel (refereegranskat)abstract
    • Synaptic damage, axonal neurodegeneration, and neuroinflammation are common features in Alzheimer's disease (AD), frontotemporal dementia (FTD), and Creutzfeldt-Jakob disease (CJD).Unicentric cohort of 353 participants included healthy control (HC) subjects, AD continuum stages, genetic AD and FTD, and FTD and CJD. We measured cerebrospinal fluid neurofilament light (NF-L), neurogranin (Ng), 14-3-3, and YKL-40 proteins.Biomarkers showed differences in HC subjects versus AD, FTD, and CJD. Disease groups differed between them except AD versus FTD for YKL-40. Only NF-L differed between all stages within the AD continuum. AD and FTD symptomatic mutation carriers presented differences with respect to HC subjects. Applying the AT(N) system, 96% subjects were positive for neurodegeneration if 14-3-3 was used, 94% if NF-L was used, 62% if Ng was used, and 53% if YKL-40 was used.Biomarkers of synapse and neurodegeneration differentiate HC subjects from neurodegenerative dementias and between AD, FTD, and CJD. NF-L and 14-3-3 performed similar to total tau when AT(N) system was applied.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 61-70 av 1860
Typ av publikation
tidskriftsartikel (1745)
forskningsöversikt (64)
konferensbidrag (27)
bokkapitel (16)
bok (7)
samlingsverk (redaktörskap) (1)
visa fler...
visa färre...
Typ av innehåll
refereegranskat (1786)
övrigt vetenskapligt/konstnärligt (74)
Författare/redaktör
Zetterberg, Henrik, ... (1521)
Ashton, Nicholas J. (205)
Andreasson, Ulf, 196 ... (163)
Hansson, Oskar (155)
Portelius, Erik, 197 ... (126)
visa fler...
Karikari, Thomas (114)
Wallin, Anders, 1950 (104)
Skoog, Ingmar, 1954 (102)
Minthon, Lennart (100)
Brinkmalm, Gunnar (85)
Mattsson, Niklas, 19 ... (80)
Kern, Silke (68)
Andreasen, Niels (68)
Gobom, Johan (66)
Hampel, Harald (60)
Lessa Benedet, André ... (59)
Zettergren, Anna, 19 ... (54)
Lantero Rodriguez, J ... (52)
Stomrud, Erik (45)
Höglund, Kina, 1976 (45)
Rosengren, Lars, 195 ... (44)
Brinkmalm-Westman, A ... (43)
Janelidze, Shorena (43)
Scheltens, Philip (42)
Teunissen, Charlotte ... (39)
Molinuevo, J. L. (38)
Palmqvist, Sebastian (37)
Engelborghs, Sebasti ... (37)
Johnson, Sterling C (36)
Shaw, Leslie M (36)
Hampel, H. (36)
Kollmorgen, G. (35)
Molinuevo, José Luis (35)
Johnson, S. C. (34)
Lleó, Alberto (34)
Scheltens, P (34)
Vanmechelen, Eugeen (33)
Kvartsberg, Hlin, 19 ... (32)
Simrén, Joel, 1996 (31)
Trojanowski, John Q (31)
Schöll, Michael, 198 ... (31)
Svensson, Johan, 196 ... (30)
Mattsson-Carlgren, N ... (30)
Asthana, S. (30)
Carlsson, Cynthia M (30)
Visser, Pieter Jelle (30)
Montoliu-Gaya, Laia (29)
Rosa-Neto, Pedro (29)
Hanrieder, Jörg, 198 ... (29)
visa färre...
Lärosäte
Göteborgs universitet (1860)
Karolinska Institutet (328)
Lunds universitet (231)
Uppsala universitet (85)
Linköpings universitet (41)
Chalmers tekniska högskola (37)
visa fler...
Örebro universitet (29)
Umeå universitet (28)
Stockholms universitet (15)
Luleå tekniska universitet (11)
Kungliga Tekniska Högskolan (7)
Jönköping University (5)
Högskolan Kristianstad (3)
Linnéuniversitetet (3)
Sveriges Lantbruksuniversitet (1)
VTI - Statens väg- och transportforskningsinstitut (1)
Sophiahemmet Högskola (1)
visa färre...
Språk
Engelska (1837)
Svenska (21)
Odefinierat språk (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (1782)
Naturvetenskap (49)
Samhällsvetenskap (33)
Teknik (4)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy